Exposed: 10 CENT Crypto to Explode April 20th?

The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…

Daniel Menold Biography and Net Worth

VP of CymaBay Therapeutics

Daniel Menold is the VP of Fin. at Cymabay Therapeutics Inc.

What is Daniel Menold's net worth?: The estimated net worth of Daniel Menold is at least $162,400.00 as of August 29th, 2018. Mr. Menold owns 5,000 shares of CymaBay Therapeutics stock worth more than $162,400 as of April 27th. This net worth approximation does not reflect any other assets that Mr. Menold may own. Learn More about Daniel Menold's net worth.
How do I contact Daniel Menold?: The corporate mailing address for Mr. Menold and other CymaBay Therapeutics executives is 7575 GATEWAY BOULEVARD SUITE 110, NEWARK CA, 94560. CymaBay Therapeutics can also be reached via phone at (510) 293-8800 and via email at [email protected]. Learn More on Daniel Menold's contact information.
Has Daniel Menold been buying or selling shares of CymaBay Therapeutics?: Daniel Menold has not been actively trading shares of CymaBay Therapeutics during the last ninety days. Most recently, Daniel Menold sold 10,000 shares of the business's stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $23.58, for a transaction totalling $235,800.00. Learn More on Daniel Menold's trading history.
Who are CymaBay Therapeutics' active insiders?: CymaBay Therapeutics' insider roster includes Janet Dorling (Director), Dennis Kim (Insider), Charles McWherter (Insider), Daniel Menold (VP), Paul Quinlan (General Counsel), Sujal Shah (CEO), and Kurt von Emster (Director). Learn More on CymaBay Therapeutics' active insiders.
Are insiders buying or selling shares of CymaBay Therapeutics?: In the last year, insiders at the biopharmaceutical company sold shares 27 times. They sold a total of 480,648 shares worth more than $7,806,823.97. The most recent insider tranaction occured on February, 12th when Director Janet Dorling sold 6,000 shares worth more than $191,820.00. Insiders at CymaBay Therapeutics own 7.0% of the company. Learn More about insider trades at CymaBay Therapeutics.
Information on this page was last updated on 2/12/2024.

Daniel Menold Insider Trading History at CymaBay Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/16/2024	Sell	10,000	$23.58	$235,800.00
12/15/2023	Sell	21,497	$21.99	$472,719.03
8/9/2023	Sell	20,945	$12.35	$258,670.75
8/29/2018	Sell	5,000	$13.00	$65,000.00	5,000

Daniel Menold Buying and Selling Activity at CymaBay Therapeutics

CymaBay Therapeutics Company Overview

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Fremont, California.

Today's Range

Now: $32.48

$32.48

50 Day Range

MA: $32.40

$32.17

$32.48

2 Week Range

Now: $32.48

$7.26

$32.50

Volume

73 shs

Average Volume

4,113,430 shs

Market Capitalization

$3.73 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.32

Exposed: 10 CENT Crypto to Explode April 20th?

From True Market Insiders | Ad